Revelation Biosciences plans Phase 2a Gemini trial in acute kidney injury for early 2027
REVB•Revelation Biosciences plans to start a Phase 2a Gemini trial in stage 2 or 3 acute kidney injury patients in early 2027, with topline results expected in late 2027. The study is expected to cost about $7 million, and the company reported $9.1 million in cash and cash equivalents as of September 30, 2026.
1. Trial plans
Revelation Biosciences plans a Phase 2a Gemini trial in patients with stage 2 or 3 acute kidney injury in early 2027. Topline results are expected in late 2027.
2. Cost and funding
The streamlined study is expected to cost approximately $7 million, compared with approximately $60 million under the previous development plan. The company reported cash and cash equivalents of $9.1 million as of September 30, 2026.
3. Development plans
Earlier clinical studies showed reduced inflammatory activity and favorable tolerability. Planned licensing and development partnerships would support Gemini, which targets an estimated $94 billion addressable market in acute kidney injury.




